Skip to main content
    I

    Ironwood Pharmaceuticals Inc (IRWD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.87
    +0.02 (+0.41%)

    Market Cap: $802.92M

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Ironwood Pharmaceuticals Inc (IRWD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ironwood Pharmaceuticals (IRWD) has a market cap of $802.92M and an enterprise value of $1.05B. Its return on invested capital of 70.49% compares with a 7.96% median across 8 similar companies. It kept 37.38% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 30.70% above the market cap, as debt exceeds cash.

    Market Cap$802.92M
    Enterprise Value$1.05B
    Latest price (Nov 17, 2026)$4.87

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.30% in the quarter ended Sep 30, 2026 and grew 1.61% a year over 2 years.

    Shares Outstanding164.90M
    Shares Change (YoY)+1.65%
    Shares Change (QoQ)+0.30%
    Share Count Growth (2Y CAGR)+1.61%

    Valuation Ratios

    The price to sales ratio is 2.0x. Its year-end P/E ranged from 9.9x to 303.4x from 2019 to 2025.

    P/E Ratio5.4x
    Forward P/E3.8x
    P/S Ratio2.0x
    Forward P/S1.6x
    P/OCF Ratio3.9x
    PEG Ratio0.3

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 4.1x EBITDA.

    EV / Earnings7.0x
    EV / Sales2.6x
    EV / EBITDA4.1x
    EV / EBIT4.2x

    Price Statistics

    The stock is up 55.10% over 52 weeks and trades 22.06% above its 50-day average.

    Beta (1Y)1.30
    52-Week Change+55.10%
    1-Month Change+36.80%
    3-Month Change+11.70%
    6-Month Change+32.70%
    5-Year Change-72.59%
    10-Year Change-72.59%
    Total Return (1Y)+55.10%
    Total Return (3Y CAGR)-20.73%
    Total Return (5Y CAGR)-16.35%
    Return vs SPY (1Y)+45.03%
    Max Drawdown (1Y)-43.60%
    Max Drawdown (3Y)-96.33%
    Sharpe Ratio (1Y)0.59
    Correlation with SPY (1Y)0.23
    50-Day Average$3.99
    200-Day Average$3.95
    52-Week Range$2.95 to $5.78
    RSI (14 Days)75.6
    Average Volume (20 Days)2.53M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.51x current liabilities.

    Current Ratio6.51x
    Quick Ratio6.51x
    Debt / EBITDA1.31x
    Interest Coverage8.28x

    Returns and Efficiency

    Return on invested capital is 70.49% over the last 12 months, against a 5-year average of -37.94%.

    Return on Assets (ROA)51.49%
    Return on Invested Capital (ROIC)70.49%
    Return on Capital Employed (ROCE)98.50%
    ROA (5Y Average)-29.98%
    ROIC (5Y Average)-37.94%
    Asset Turnover1.17x
    Receivables Turnover3.26x

    Taxes

    Income tax took 34.07% of pretax income over the last 12 months.

    Income Tax (TTM)$77.33M
    Effective Tax Rate34.07%

    Scores

    IRWD has an Altman Z-Score of -1.06, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-1.06
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $400.30M over the last 12 months is up 18.09% from the 12 months before.

    Revenue$400.30M
    Revenue Growth (YoY)+18.09%
    Gross Profit$400.30M
    Operating Income$251.82M
    Pretax Income$226.95M
    Net Income$149.63M
    EBITDA$253.84M
    EBIT$252.02M
    Reported EPS (TTM)$0.90

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$86.38M
    Total Debt$332.91M
    Net Debt$246.53M
    Net Debt Per Share$1.50
    Working Capital$191.26M
    Shareholder Equity-$97.19M
    Tangible Book Value-$98.62M
    Total Assets$290.59M
    Total Liabilities$387.79M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$205.37M
    FCF Per Share$1.24
    Depreciation and Amortization$1.82M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 62.91%, against a 5-year average of -7.34%.

    Gross Margin100.00%
    Operating Margin62.91%
    Pretax Margin56.70%
    Net Margin37.38%
    EBITDA Margin63.41%
    EBIT Margin62.96%
    Operating Margin (5Y Average)-7.34%
    Net Margin (5Y Average)-10.86%

    Growth

    Revenue fell 10.32% a year over 3 years, and EPS 38.11% a year.

    Revenue Growth (3Y CAGR)-10.32%
    Revenue Growth (5Y CAGR)-5.33%
    EPS Growth (3Y CAGR)-38.11%
    EPS Growth (5Y CAGR)-21.87%
    FCF Growth (3Y CAGR)-22.57%
    FCF Growth (5Y CAGR)-5.33%
    Operating Income Growth (3Y CAGR)-26.72%

    Revenue and profit by year

    Dividends and Yields

    IRWD does not pay a dividend.

    Earnings Yield18.52%
    Buyback Yield-0.05%
    Shareholder Yield-0.05%

    Peer Position

    Against 9 similar companies, IRWD has the 8th highest P/E.

    P/E Ratio5.4x vs 12.8x median
    P/S Ratio2.0x vs 2.0x median
    ROIC70.49% vs 7.96% median
    Revenue Growth (Trailing 4 Quarters, YoY)+18.09% vs +12.08% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 30.48% and EPS growth at 160.99% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+30.48%
    EPS Growth Forecast (2Y CAGR)+160.99%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRWD

    What is IRWD's market cap?

    Ironwood Pharmaceuticals has a market cap of $802.92M. Its enterprise value, which adds debt and subtracts cash, is $1.05B.

    What is IRWD's P/E ratio?

    Ironwood Pharmaceuticals has a trailing P/E ratio of 5.4x and a forward P/E of 3.8x.

    How many shares of IRWD are outstanding?

    Ironwood Pharmaceuticals has 164.90M shares outstanding. The count is up 1.65% from a year earlier.

    Does IRWD pay a dividend?

    No. Ironwood Pharmaceuticals does not pay a dividend.

    How much debt does IRWD have?

    Ironwood Pharmaceuticals has $332.91M of total debt and $86.38M of cash and equivalents, a net debt position of $246.53M.